- Advertisement -

Pfizer and its German partner BioNTech shared the results of a Phase III trial of their COVID-19 vaccine booster on Thursday, saying the additional third dose showed 95.6% efficacy against symptomatic disease.

advertisement

The trial involved more than 10,000 people 16 years of age and older who had previously received the Pfizer-BioNTech primary two-dose vaccine. Pfizer said the booster “restored vaccine protection against COVID-19 to the high level achieved after the second dose, showing a relative vaccine efficacy of 95.6% compared to those who did not receive the booster.”

- Advertisement -

“These results provide further evidence of the benefits of boosters as we aim to keep people safe from this disease,” said Pfizer CEO Albert Boerla. said in a statement. “In addition to our efforts to increase global reach and advance among the uneducated, we believe boosters have an important role to play in addressing the ongoing public health threat of this pandemic.”

Bourla said Pfizer-BioNtech plans to share the results with global health officials in support of the “rollout of booster doses around the world.”

FILE – A nurse prepares to give a Pfizer booster shot on October 6, 2021 at Northwell Health in New Hyde Park, New York. (Photo by Alejandra Villa Lorca / Newsday RM via Getty Images)

Of the roughly 190 million Americans who have been fully vaccinated against COVID-19, most have received the Pfizer or Moderna alternatives, while about 15 million have received the Johnson & Johnson vaccine.

The government says all three US vaccines offer strong protection against hospitalization and death from COVID-19, and the priority is getting the first shot to the 66 million eligible but unvaccinated Americans who are most at risk. Huh. But with the spread of the extra-infectious delta variant and signs of reduced immunity against mild infections, the nation is moving towards a massive booster campaign.

Last month, US seniors and young adults at high risk from COVID-19 because of poor health, job or living conditions began to offer the Pfizer booster – at least six months after their initial vaccination. Last week, an FDA advisory panel recommended a similar approach for the half-dose of Moderna Booster.

related: FDA Approves Moderna, J&J Boosters to Combine COVID-19 Vaccines

This is a developing story. Check back for updates.